InspireMD, Inc. (NSPR)
NASDAQ: NSPR · Real-Time Price · USD
2.690
-0.060 (-2.23%)
Apr 1, 2025, 10:23 AM EDT - Market open
InspireMD Revenue
In the year 2024, InspireMD had annual revenue of $7.01M with 12.96% growth. InspireMD had revenue of $1.95M in the quarter ending December 31, 2024, with 10.68% growth.
Revenue (ttm)
$7.01M
Revenue Growth
+12.96%
P/S Ratio
16.09
Revenue / Employee
$81,500
Employees
86
Market Cap
79.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.01M | 804.00K | 12.96% |
| Dec 31, 2023 | 6.21M | 1.03M | 20.00% |
| Dec 31, 2022 | 5.17M | 676.00K | 15.04% |
| Dec 31, 2021 | 4.50M | 2.01M | 80.89% |
| Dec 31, 2020 | 2.49M | -1.24M | -33.22% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
NSPR News
- 6 days ago - InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 19 days ago - InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures - GlobeNewsWire
- 4 months ago - InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) - GlobeNewsWire
- 4 months ago - InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors - GlobeNewsWire